NEW THERAPIES FOR DIABETES: BEYOND INJECTABLE INSULIN AND ORAL ANTIDIABETICS

作者：Feliciano Alfonso John Edwin; Sierra Ariza Ivan Dario

来源：Revista da Associacao Medica Brasileira, 2008, 54(5): 447-454.

• Hypoglycemic agents
• Diabetes mellitus type 1
• Diabetes mellitus type 2
• Glucagon-like peptide 1
• Dipeptidyl peptidase IV
• Insulin

New medicines for the therapy of the type 1 and type 2 diabetes have been incorporated in the list of traditional drugs: oral agents and injectable insulin. These treatment alternatives have a new mechanism of action that takes advantage of the antidiabetic properties of certain peptides such as amylin and glucagon like peptide-1 (GLP-1), whose levels are wanting or insufficient in diabetes. This is attained through amylin and GLP-1 analogues, although it can also be achieved by inhibiting the enzyme that degrades the latter. Furthermore, a new system to administer insulin in a noninvasive way through inhalation has become available in the market. This paper summarizes the most important and updated findings on the action mechanism, efficacy, adverse effects and indications of these innovative drugs. [Rev Assoc Med Bras 2008; 54( 5): 447-54]

• 出版日期2008-10